Diabetes: Most Read Stories From 2024

Know Labs Announces Wearable, Non-Invasive Continuous Glucose Monitor

Earlier this year in February, Know Labs, Inc. announced the release of its KnowU continuous glucose monitor (CGM). As yet another technological advancement within the diabetes space, Know Labs’ CGM is equipped with on-board computing power and machine learning capabilities that allow patients to receive the most instantaneous and accurate information than ever before.

Top read diabetes stories from the year 2024 | image credit: Gatot / stock.adobe.com

Transforming Diabetes Interventions Into Sustainable Programs for Pharmacy

At the 2024 National Association of Chain Drug Stores Total Store Expo, Drug Topics caught up with Jon Easter, Professor of Practice; Vice Chair, Practice Advancement at UNC Eshelman School of Pharmacy, to discuss the importance of diabetes programming in the community pharmacy setting. Easter explored how diabetes presents an opportunity for pharmacists to practice at the top of their license through the utilization of community programming.

CGM Can Help Pregnant Patients With T1D Improve TIR, Outcomes

While patients living with type 1 diabetes (T1D) are typically keeping a close eye on their daily health, pregnant women with T1D are especially health-conscious. With new CGM technology easing the diabetes burden for millions of patients, researchers are now discovering that the same technology can improve pregnancy outcomes as well. They noted a 5-unit increase in the CGM’s time-in-range for this specific population.

Comprehensive Medication Reviews Can Help Improve Adherence in Patients With T2D

As previously mentioned, patients living with diabetes—either type 1 or type 2—are encouraged to make their health a number 1 priority, whether that involves taking necessary medications or meeting with the appropriate providers. However, patients with diabetes who have significant health literacy can still tend to fall behind when it comes to medication adherence. This issue has led researchers to suggest the use of comprehensive medication reviews to drive the adherence of oral antidiabetic medications.

Teva Pharmaceuticals Launches Liraglutide Injection 1.8 mg, First Generic GLP-1 in the US

In the summer of 2024, Teva Pharmaceuticals made a noteworthy announcement when it introduced the US’ first generic glucagon-like peptide-1 (GLP-1). The liraglutide (Victoza) injection was approved in June for adults and children aged 10 years and older with T2D. Furthermore, researchers noted the drug’s possibility of improving cardiovascular outcomes—a promising hope for the future of GLP-1s in the pharmaceutical supply chain.

Pharmacy practice is always changing. Stay ahead of the curve: Sign up for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.